CareTria acquired CaryHealth to create an integrated AI-powered direct-to-patient pharmacy platform aimed at streamlining prescription-to-therapy initiation and adherence. The combined system is designed to reduce fragmentation across hub, telehealth, patient support, and dispensing workflows. CareTria said CaryHealth’s AI-enabled digital pharmacy technology will connect benefit investigation, patient engagement, and fulfillment through cash-payment options and multi-modal dispensing across the U.S. The company reported automated benefit investigations completed in under 60 seconds for many cases and highlighted its therapy initiation conversion performance tied to its cash model. The acquisition also targets continuity of care during coverage disruptions and adds reporting connectivity for manufacturers. While the deal is structured as an operational integration rather than a clinical asset purchase, it directly affects commercialization speed for therapies where access and adherence determine real-world outcomes. For biotech teams relying on patient support and specialty distribution, the platform’s claim of reduced drop-off between prescription and initiation signals a continuing shift toward vertically integrated access layers.